首页> 外文期刊>European journal of emergency medicine: Official journal of the European Society for Emergency Medicine >Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study.
【24h】

Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study.

机译:严重地高辛中毒的紧急分步特异性免疫疗法:一项观察性队列研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate the efficacy and safety of a step-by-step fixed dose of specific immunotherapy protocol in case of severe digoxin poisoning in an open uncontrolled prospective study. METHODS: Twenty consecutive patients were admitted because of severe digoxin poisoning. The inclusion criteria were: digoxin overdose and either life-threatening arrhythmia; high-degree atrioventricular block, ventricular arrhythmia, or bradycardia less than 50 bpm and hyperkalaemia (>5.5 mmol/l). A two-step protocol of antidigoxin antibodies treatment was carried out. At admission, every patient received two vials of specific Fab-fragments. If after 1 h following infusion ECG signs regressed, no more treatment was given. If ECG signs did not regress, patients were given two more vials. At inclusion and 6 h after immunotherapy, clinical (cardiac rhythm, ECG records) and biological (serum digoxin concentration, potassium) findings were recorded. RESULTS: Patients had a median (interquartile range) age of 83 (75-90) years. Four patients had acute poisoning and 16 chronic overdoses. Eleven patients showed ventricular arrhythmia, and five had high-degree atrioventricular block. Seventy percent of the patients needed only the first step. Significant decreases were observed in the number of cardiac dysrhythmia (16 vs. three patients), in the median (interquartile range) of serum digoxin concentration [5 microg/l (3.8-6.2) vs. 0.4 microg/l (0.3-2.2)] and in serum potassium [4.6 mmol/l (4.1-5.5) vs. 3.85 mmol/l (3.7-4.55)] before and after immunotherapy. The digoxin-related mortality was 5%. CONCLUSION: This protocol of step-by-step digoxin-specific immunotherapy seems to be as effective as the equimolar treatment, and there was significant cost reduction in case of acute poisoning.
机译:目的:在公开的非对照前瞻性研究中,评估分步固定剂量的特异性免疫疗法方案在严重地高辛中毒情况下的疗效和安全性。方法:连续20例患者因严重的地高辛中毒而入院。纳入标准为:地高辛过量和危及生命的心律不齐;高度房室传导阻滞,室性心律不齐或心动过缓小于50 bpm和高钾血症(> 5.5 mmol / l)。进行了抗地高辛抗体治疗的两步方案。入院时,每位患者均接受两瓶特定的Fab片段。如果输注后1小时ECG征象消退,则不再给予治疗。如果心电图征象没有消退,则再给患者两个小瓶。入选时和免疫治疗后6小时,记录临床(心脏节律,心电图记录)和生物学(血清地高辛浓度,钾)结果。结果:患者的中位年龄(四分位间距)为83(75-90)岁。 4例患者出现急性中毒和16例慢性过量。 11例出现室性心律失常,5例发生高度房室传导阻滞。 70%的患者仅需要第一步。观察到心律失常的数量显着减少(16名患者与3名患者),血清地高辛浓度的中位数(四分位间距)[5 microg / l(3.8-6.2)与0.4 microg / l(0.3-2.2) ]和免疫治疗前后的血清钾浓度[4.6 mmol / l(4.1-5.5)对3.85 mmol / l(3.7-4.55)]。地高辛相关的死亡率为5%。结论:这种循序渐进的地高辛特异性免疫疗法方案似乎与等摩尔疗法一样有效,并且在急性中毒的情况下可显着降低成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号